Editorial comment by Albersen, Maarten
11
1
1
2
2
2
2
2
2
2
2
2
2
3
o
o
c
s
v
t
a
l
t
1
18. Traish AM, Park K, Dhir V, et al. Effects of castration and andro-
gen replacement on erectile function in a rabbit model. Endocri-
nology. 1999;140:1861-1868.
9. Moreland RB, Traish A, McMillin MA, et al. PGE1 suppresses the
induction of collagen synthesis by transforming growth factor-beta 1 in
human corpus cavernosum smooth muscle. J Urol. 1995;153:826-834.
10. Jung GW, Kwak JY, Yoon S, et al. IGF-I and TGF-beta2 have a key role
on regeneration of nitric oxide synthase (NOS)-containing nerves after
cavernous neurotomy in rats. Int J Impot Res. 1999;11:247-259.
11. Dahiya R, Chui R, Perinchery G, et al. Differential gene expression
of growth factors in young and old rat penile tissues is associated
with erectile dysfunction. Int J Impot Res. 1999;11:201-206.
12. Lee MC, El-Sakka AI, Graziottin TM, et al. The effect of vascular
endothelial growth factor on a rat model of traumatic arteriogenic
erectile dysfunction. J Urol. 2002;167:761-767.
13. Rogers RS, Graziottin TM, Lin CS, et al. Intracavernosal vascular
endothelial growth factor (VEGF) injection and adeno-associated
virus-mediated VEGF gene therapy prevent and reverse venogenic
erectile dysfunction in rats. Int J Impot Res. 2003;15:26-37.
4. Hood JD, Meininger CJ, Ziche M, et al. VEGF upregulates ecNOS
message, protein, and NO production in human endothelial cells.
Am J Physiol. 1998;274:H1054-H1058.
5. van der Zee R, Murohara T, Luo Z, et al. Vascular endothelial
growth factor/vascular permeability factor augments nitric oxide
release from quiescent rabbit and human vascular endothelium.
Circulation. 1997;95:1030-1037.
6. Burchardt M, Burchardt T, Chen MW, et al. Expression of mes-
senger ribonucleic acid splice variants for vascular endothelial
growth factor in the penis of adult rats and humans. Biol Reprod.
1999;60:398-404.
17. Liu X, Lin CS, Graziottin T, et al. Vascular endothelial growth
factor promotes proliferation and migration of cavernous smooth
muscle cells. J Urol. 2001;166:354-360.
18. Rajasekaran M, Kasyan A, Jain A, et al. Altered growth factor
expression in the aging penis: the Brown-Norway rat model. J
Androl. 2002;23:393-399.
9. Park K, Ahn KY, Kim MK, et al. Intracavernosal injection of
vascular endothelial growth factor improves erectile function in
aged rats. Eur Urol. 2004;46:403-407.
0. Mills TM, Wiedmeier VT, Stopper VS. Androgen maintenance of
erectile function in the rat penis. Biol Reprod. 1992;46:342-348.
1. Muller SC, Hsieh JT, Lue TF, et al. Castration and erection. An
animal study. Eur Urol. 1988;15:118-124.
2. Mills TM, Lewis RW, Stopper VS. Androgenic maintenance of
inflow and Veno-occlusion during erection in the rat. Biol Reprod.
1998;59:1413-1418.
3. Nehra A, Goldstein I, Pabby A, et al. Mechanisms of venous
leakage: a prospective clinicopathological correlation of corporeal
function and structure. J Urol. 1996;156:1320-1329.
4. Moreland RB. Is there a role of hypoxemia in penile fibrosis: a
viewpoint presented to the society for the Study of Impotence. Int
J Impot Res. 1998;10:113-120.
5. Siroky MB, Azadzoi KM. Vasculogenic erectile dysfunction: newer
therapeutic strategies. J Urol. 2003;170:S24-S29; [Discussion:
S9-30].
6. Ruohola JK, Valve EM, Karkkainen MJ, et al. Vascular endothelial
growth factors are differentially regulated by steroid hormones and
antiestrogens in breast cancer cells. Mol Cell Endocrinol. 1999;149:
29-40.
7. Haggstrom S, Lissbrant IF, Bergh A, et al. Testosterone induces
vascular endothelial growth factor synthesis in the ventral prostate
in castrated rats. J Urol. 1999;161:1620-1625.
8. Sordello S, Bertrand N, Plouet J. Vascular endothelial growth
factor is up-regulated in vitro and in vivo by androgens. Biochem
Biophys Res Commun. 1998;251:287-290.
9. Kurz B, Lemke AK, Fay J, et al. Pathomechanisms of car-
tilage destruction by mechanical injury. Ann Anat. 2005;187:
473-485.
3860. Pufe T, Kurz B, Petersen W, et al. The influence of biomechanical
parameters on the expression of VEGF and endostatin in the bone
and joint system. Ann Anat. 2005;187:461-472.
EDITORIAL COMMENT
Penile erection is a complex neurovascular phenomenon that
depends on the balance and integration of multiple overlapping
control systems, including neurotransmitters, vasoactive agents,
and endocrine factors. The link between testosterone (deple-
tion and supplementation) and erectile function has been ex-
tensively studied in preclinical research. Nevertheless, consid-
erable gaps in our understanding of these interactions remain to
be elucidated. In either surgically or medically castrated animal
models, it has been demonstrated that androgen deprivation
results in a significant reduction in trabecular smooth muscle
content and a marked increase in connective tissue deposition
in the corpus cavernosum.1 These changes ultimately lead to
impaired sinusoidal expandability and thus corporeal veno-
occlusive dysfunction (CVOD).2 Other changes that have been
bserved in orchiectomized animals include the accumulation
f adipocyte-like cells in the subtunical regions of the corpus
avernosum3 and structural changes in the penile nerves.4
In this study, the authors elucidate in an elegant fashion one
of the missing links in our understanding of how androgens are
involved in the regulation of penile erection.5 They demon-
trate the critical role testosterone plays in regulation of penile
ascular endothelial growth factor (VEGF) expression on both
ranscriptional (mRNA) and translational (protein) levels. The
uthors suggest that VEGF is expressed by endothelial cells
ining the sinus; however, when reviewing the histology figure,
he multilayered aspect of the stained perisinusoidal cells (Fig.
A in5) suggests that expression may be present in the suben-
dothelial cavernous smooth muscle. Thus, in addition to the
conclusions drawn by the authors, VEGF may further play a
role in maintenance of smooth muscle content and function.
The specific tissue and cell types regulated by VEGF need to be
further investigated in future research. Furthermore, erectile
function is significantly compromised 1 week postcastration and
returns to normal after 1 week of androgen replacement. Be-
cause these intervals are rather short, this raises the question of
whether trophic changes induced by VEGF are the capital
pathway of the effects of testosterone replacement on erectile
function, or whether direct functional effects of androgens
possibly play an additional role.
Rogers et al previously reported that both VEGF and VEGF
gene therapy in castrated rats prevented and reversed venogenic
erectile dysfunction as illustrated by an increased response to
papaverine injection and a significantly decreased venous leak-
age.2 In the latter study, VEGF (gene) therapy resulted in
recovery of endothelial, neural, and smooth muscle structure,
and decreased penile fibrosis after castration. These results
replicate those found in studies using testosterone supplemen-
tation in castrated animals.6
Thus, it is becoming increasingly apparent that androgens
regulate and maintain penile structure and function at least
partially through interference with paracrine signaling in the
erectile tissue. Of note, however, is that castration in rodents
produced demonstrable changes in penile structure and reduced
erectile function. This may be attributed to the fact that the
rodents’ adrenal glands do not produce sufficient androgen.7Translation of these results to the human should therefore be
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done with caution. As the authors mention, further studies are
required to fully understand the complex interactions between
androgens and paracrine signaling in the erectile tissue.
Maarten Albersen, M.D., Laboratory of Experimental
Urology, Department of Urology, University Hospitals,
Leuven, Belgium
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